TY - JOUR T1 - Current surgical practice for children born with a cleft lip and/or palate in the United Kingdom JF - medRxiv DO - 10.1101/2021.10.10.21264828 SP - 2021.10.10.21264828 AU - Matthew Fell AU - Alex Davies AU - Amy Davies AU - Shaheel Chummun AU - Alistair R.M. Cobb AU - Kanwalraj Moar AU - Yvonne Wren Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/13/2021.10.10.21264828.abstract N2 - Background This study describes primary surgical reconstructions performed for children born with a cleft lip and/or palate in the United Kingdom.Methods Data were obtained from the Cleft Collective, a national longitudinal cohort study. Data forms completed at the time of surgery included details on timing, technique and adjuncts used during the operative period. Demographic data on participants were validated via parental questionnaires.Results Between 2015 and 2021, 1782 Cleft Collective surgical forms were included, relating to the primary reconstructions of 1514 individual children. The median age at primary cheiloplasty was 4.3 months. Unilateral cleft lips were reconstructed with an anatomical subunit approximation technique in 53%, whereas bilateral cleft lips were reconstructed with a broader range of eponymous techniques. Clefts of the soft palate were reconstructed at a median age of 10.3 months with an intravelar veloplasty in 94% cases. Clefts of the hard palate were reconstructed with a vomer flap in 84% cases in a bi-modal age distribution, relating to reconstruction carried out simultaneously with either lip or soft palate reconstruction. Antibiotics were used in 96% of cases, with an at-induction-only regimen used more commonly for cheiloplasties (p<0.001) and a 5–7day post-operative regime used more commonly for soft palatoplasties (p<0.001). Peri-operative steroids were used more commonly in palatoplasties than cheiloplasties (p<0.001) but tranexamic acid use was equivalent (p=0.73).Conclusion This study contributes to our understanding of current cleft surgical pathways in the United Kingdom and will provide a baseline for analysis of the effectiveness of utilised protocols.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMatthew Fell is supported by the VTCT Foundation for a research fellowship with the Cleft Collective. All other authors did not receive support from any organisation for the submitted work. Funders had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The authors can confirm their independence from funders and that all authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and accuracy of the data analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to establish the Cleft Collective Cohort Study was granted by the Southwest Central Bristol Ethics Committee (13/SW/0064). Global research and development (R&D) approval was provided by University Hospitals Bristol NHS Foundation Trust. Local R&D approvals were subsequently obtained from each National Health Service (NHS) Trust. National ethical approval (IRAS project ID259689) to analyse this subset of data (Cleft Collective Project Number CC015) was approved by the NHS Health Research Authority.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -